Val401
Status
Phase 2 - ready
QoL palliative care/cachexia in pancreatic cancer
Indication
About VAL401
VAL401 is the reformulation of the established anti-psychotic drug risperidone. Formulated into a lipid-filled capsule for oral, once daily administration, VAL401 enables an anti-cancer activity, via cancer cell metabolism enzyme, Hydroxysteroid-dehydrogenase type 10 (HSD10), not seen with conventional risperidone.
VAL401 has completed a small Phase 2 clinical trial, treating patients with end-stage non-small cell lung cancer. These patients demonstrated a statistically significant improvement in overall survival from diagnosis over case-matched control patients in the same clinics; and showed improvements in quality of life during treatment.
Identifying quality of life improvement in nausea, pain and appetite, has identified pancreatic adenocarcinoma to be a preferred disease to assess in the next clinical trial of VAL401.
The VAL401 asset consists of clinical data and intellectual property, including the patent portfolio, technical specifications and know-how.
Indication
Stage 3-4 pancreatic cancer patients, quality of life palliative care/cachexia
Dilly, S. J., Morris, G. S., Taylor, P. C., Parmentier, F., Williams, C. and Afshar, M. (2019) Clinical Pharmacokinetics of a Lipid-Based Formulation of Risperidone, VAL401: Analysis of a Single Dose in an Open-Label Trial of Late-Stage Cancer Patients, European journal of drug metabolism and pharmacokinetics. U.S. National Library of Medicine. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC6616216/ (Accessed: 30 October 2024).
Dilly SJ;Clark AJ;Marsh A;Mitchell DA;Cain R;Fishwick CWG;Taylor PC; (2017) A chemical genomics approach to drug reprofiling in oncology: Antipsychotic drug risperidone as a potential adenocarcinoma treatment, Cancer letters. U.S. National Library of Medicine. Available at: https://pubmed.ncbi.nlm.nih.gov/28188816/ (Accessed: 30 October 2024).